Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Researchers discover HS1.2 enhancer as the cause of SLE

Researchers discover HS1.2 enhancer as the cause of SLE

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

Mycophenolate mofetil superior to azathioprine for lupus nephritis

Mycophenolate mofetil superior to azathioprine for lupus nephritis

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Allos third quarter net loss decreases to $11.2 million

Allos third quarter net loss decreases to $11.2 million

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC